Type1diabetes

Metabolic Diseases
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
Stem cells from human exfoliated teethPhase 11 trial
Active Trials
NCT03912480UnknownEst. Mar 2021
Diabeloop
DiabeloopFrance - Grenoble
1 program
DBLG1 SystemN/A1 trial
Active Trials
NCT04749693RecruitingEst. Jan 2026
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Infusion of GIP[1-42], GIP[1-30] or placeboN/A1 trial
Active Trials
NCT06137586Completed10Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
T-TherapeuticsStem cells from human exfoliated teeth
Novo NordiskInfusion of GIP[1-42], GIP[1-30] or placebo
DiabeloopDBLG1 System

Clinical Trials (3)

Total enrollment: 10 patients across 3 trials

NCT03912480T-TherapeuticsStem cells from human exfoliated teeth

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Start: Jan 2019Est. completion: Mar 2021
Phase 1Unknown
NCT06137586Novo NordiskInfusion of GIP[1-42], GIP[1-30] or placebo

The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes

Start: Aug 2022Est. completion: May 202410 patients
N/ACompleted

Observational Study of the Use of DBLG1 System in Real Life

Start: May 2021Est. completion: Jan 2026
N/ARecruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 10 patients
3 companies competing in this space